HDAC9 and endometrial cancer: For instance, in ovarian cancer, histone acetylation promotes oncogene expression, while dysregulated histone deacetylase (HDAC) activity is implicated in ovarian and endometrial cancers, positioning HDAC inhibitors as promising therapies.30